S

Sanofi

Global pharma company; vaccines and R&D

Patient Privacy Officer & Counsel

Full-TimeDeadline 10/30/26
$161.3k - $232.9k
Senior
JD
Cambridge, MA, USA+1 moreMore locations: Morristown, NJ, USA
In Person
LegalLegal Counsel & Legal Support

About the job

Requirements
  • A Juris Doctorate degree from an accredited law school, or an equivalent advanced degree in law, and a valid license to practice law in the United States.
  • At least 7 years of professional experience, including significant experience in data privacy.
  • In-depth knowledge of United States state and federal privacy laws and regulations, including the California Consumer Privacy Act and the Health Insurance Portability and Accountability Act, and familiarity with artificial intelligence regulations and ethical frameworks.
  • Understanding and working experience of the research and development journey of a new drug, from definition of the drug candidate to product registration and safety, in a regulated research and development setting subject to Good Clinical Practices.
  • Demonstrated experience applying privacy principles and regulations in research and development.
  • Ability to navigate tensions, align stakeholders, and drive coordinated action toward resolution.
  • Communication and stakeholder-management skills to establish credibility and drive decisions with senior internal stakeholders, balancing executive presence with a solutions-oriented approach.
  • Advocacy skills with external stakeholders, including regulators and industry peers, to influence future regulations and shape the healthcare ecosystem.
  • Ability to translate regulatory, societal, and technological changes in biomedical research into patient privacy risk profiles, and to identify long-term risk mitigations and opportunity strategies.
Responsibilities
  • Act as a global officer and expert on data privacy, promote and maintain a culture of privacy throughout the patient data life cycle, and apply thoughtful risk-taking and a patient-centric approach.
  • Serve as the business partner for several research and development and/or medical departments, with end-to-end accountability for privacy activities in the area, including privacy by design for new projects and monitoring and reporting risk-management strategies to senior research and development leaders.
  • Drive cross-functional privacy initiatives for responsible use of patient data, informed by patient perspectives, ethical and regulatory standards, and cross-functional alignment, to protect patient rights and maintain trust while enabling innovation.
  • Monitor privacy risks in the assigned area.
  • Partner with local Privacy Officers and Legal teams to ensure supported global patient initiatives comply with local practices and regulations, and to offer local resolutions.
  • Co-author internal position papers with Legal, Research and Development, and Government Affairs, and represent Sanofi in industry advocacy with trade associations, patient association groups, and data protection regulators.
  • Oversee patient rights requests from the assigned areas, ensuring patient rights are upheld in line with regulatory requirements and Sanofi’s privacy commitments.
  • Drive effective closure of action plans arising from regulatory inspections and internal audits.
Desired Qualifications
  • A relevant privacy certification such as CIPP/US, CIPP/E, CIPM, or equivalent.
  • Additional experience in patient programs.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)